Dr. Faridar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6560 Fannin St
Ste 802
Houston, TX 77030Phone+1 713-441-1150Fax+1 713-793-7012
Education & Training
- Methodist Hospital (Houston)Fellowship, Dementia Translational Fellowship, 2017 - 2018
- Methodist Hospital (Houston)Residency, Neurology, 2013 - 2017
- University of California San Francisco School of MedicinePost-Doctoral Fellowship, 2011 - 2013
- Tehran University of Medical Sciences School of MedicineClass of 2008
Certifications & Licensure
- TX State Medical License 2017 - 2026
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- BrightFocus Alzheimer Disease Research Fellowship Award 2019
- American Neurology Association (ANA) travel award 2013
Clinical Trials
- Phase II Clinical Trial of Interleukin-2 in AD Start of enrollment: 2022 Jan 01
Roles: Contact, Principal Investigator
- Systemic and Central Inflammation in AD Start of enrollment: 2023 Mar 17
Roles: Contact
- IL-2 Plus Abatacept in FTD Start of enrollment: 2024 May 06
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 46 citationsRestoring regulatory T-cell dysfunction in Alzheimer's disease through ex vivo expansion.Alireza Faridar, Aaron D. Thome, Weihua Zhao, Jason R. Thonhoff, David R. Beers
Brain Communications. 2020-07-01 - 46 citationsFunctional alterations of myeloid cells during the course of Alzheimer’s diseaseAaron D. Thome, Alireza Faridar, David R. Beers, Jason R. Thonhoff, Weihua Zhao
Molecular Neurodegeneration. 2018-11-13 - 20 citationsEx vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's disease.Alireza Faridar, Matthew Vasquez, Aaron D Thome, Zheng Yin, Hui Xuan
Acta Neuropathologica Communications. 2022-09-30
Press Mentions
- Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy TrialApril 3rd, 2023
- Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s DiseaseJune 10th, 2023
- Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceMarch 1st, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: